Make a donation

Tuesday, January 24 2017

Myeloma Matters : January 2017

  • Myeloma Canada's Patient Advisory Council (PAC) 2016 Year in Review and leadership Changes 
  • Health Canada has approved Revlimid® plus dexamethasone as a first-line treatment for newly diagnosed patients with multiple myeloma, not eligible for translplant.
  • Revlimid® as first-line treatment for non-transplant eligible myeloma patients now funded in Newfoundland and New Brunswick
  • Volunteer with the 2017 Multiple Myeloma
  • Donate a car to Myeloma Canada, it won't cost you a penny!